for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Rigel Pharmaceuticals, Inc.

RIGL.OQ

Latest Trade

2.54USD

Change

-0.06(-2.31%)

Volume

7,324,215

Today's Range

2.37

 - 

2.61

52 Week Range

1.24

 - 

5.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Rigel Pharmaceuticals - May Offer & Sell Shares Of Common Stock Having Offering Price Of Upto $65 Million From Time To Time Through Jefferies

Aug 4 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL PHARMACEUTICALS - MAY OFFER & SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE OF UPTO $65 MILLION FROM TIME TO TIME THROUGH JEFFERIES.RIGEL PHARMACEUTICALS INC - MAY OFFER AND SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $65 MILLION FROM TIME TO TIME.

Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, And Overviews Covid-19 Program

Aug 4 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS, PROVIDES BUSINESS UPDATE, AND OVERVIEWS COVID-19 PROGRAM.Q2 REVENUE $16 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13.7 MILLION.Q2 LOSS PER SHARE $0.10.Q2 EARNINGS PER SHARE ESTIMATE $-0.13 -- REFINITIV IBES DATA.

Rigel Announces Investigator-Sponsored Trial Of Fostamatinib In Patients With Covid-19 Pneumonia

July 14 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL ANNOUNCES INVESTIGATOR-SPONSORED TRIAL OF FOSTAMATINIB IN PATIENTS WITH COVID-19 PNEUMONIA.RIGEL PHARMACEUTICALS INC - HIGH CONTENT SCREEN IDENTIFIES FOSTAMATINIB AS A CANDIDATE FOR REPURPOSING FOR ACUTE LUNG INJURY.RIGEL PHARMACEUTICALS INC - INITIATION OF INVESTIGATOR-SPONSORED TRIAL BEING CONDUCTED BY IMPERIAL COLLEGE LONDON.

Rigel Reports First Quarter 2020 Financial Results

May 5 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 REVENUE $55.8 MILLION VERSUS REFINITIV IBES ESTIMATE OF $56.7 MILLION.Q1 EARNINGS PER SHARE $0.13.Q1 EARNINGS PER SHARE ESTIMATE $0.13 -- REFINITIV IBES DATA.AS OF MARCH 31, 2020, RIGEL HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $95.9 MILLION.

Rigel Reports Q4 Loss Per Share $0.10

Feb 27 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 LOSS PER SHARE $0.10.Q4 EARNINGS PER SHARE ESTIMATE $-0.08 -- REFINITIV IBES DATA.

Grifols To Launch Tavlesse In Europe

Jan 16 (Reuters) - Grifols SA <GRLS.MC>: :SAYS EUROPEAN COMMISSION HAS APPROVED TAVLESSE (FOSTAMATINIB) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS .SAYS GRIFOLS GAINED EXCLUSIVE RIGHTS TO TAVLESSE IN ITP AND OTHER PIPELINE INDICATIONS IN EUROPE AND TURKEY AS A RESULT OF THE COLLABORATION AND LICENSE AGREEMENT REACHED WITH RIGEL PHARMACEUTICALS IN JANUARY 2019 nFWN1ZN0IO.SAYS TAVLESSE LAUNCH IS EXPECTED TO BE IN Q2 OF THIS YEAR.

Rigel Pharmaceuticals Sees Q4 Revenue Of About $15.4 Mln

Jan 13 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::SEES Q4 2019 REVENUE ABOUT $15.4 MILLION.RIGEL PHARMACEUTICALS- COMPANY EXPECTS TO REPORT Q4 NET PRODUCT SALES OF ABOUT $13.8 MILLION, COMPARED TO $7.3 MILLION IN SAME PERIOD OF 2018.RIGEL PHARMACEUTICALS- CONTRACT REVENUES FROM COLLABORATIONS FOR QUARTER ENDED DEC 31 EXPECTED TO BE ABOUT $1.6 MILLION.RIGEL PHARMACEUTICALS- EXPECTS TO REPORT CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31 OF ABOUT $98 MILLION.PHASE 3 PIVOTAL TRIAL FOR WARM AIHA ON TRACK WITH 20 PATIENTS ENROLLED.RIGEL PHARMACEUTICALS - HAS RECEIVED EC APPROVAL OF ITS MARKETING AUTHORIZATION APPLICATION FOR FOSTAMATINIB.RIGEL PHARMACEUTICALS -WITH EC APPROVAL OF FOSTAMATINIB, CO WILL RECEIVE MILESTONE PAYMENT OF $20 MILLION BASED ON TERMS OF ITS COLLABORATION WITH GRIFOLS.

Rigel Pharmaceuticals Inc Reports Q3 Loss Per Share Of $0.07

Nov 5 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.07.Q3 EARNINGS PER SHARE ESTIMATE $-0.11 -- REFINITIV IBES DATA.QTRLY TOTAL REVENUES $20.9 MILLION VERSUS $4.9 MILLION.Q3 REVENUE VIEW $16.4 MILLION -- REFINITIV IBES DATA.

Rigel Secures Credit Facility For Up To $60 Mln

Oct 2 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL SECURES CREDIT FACILITY FOR UP TO $60 MILLION.RIGEL PHARMACEUTICALS INC - HAS ENTERED INTO A $60 MILLION TERM LOAN CREDIT FACILITY WITH MIDCAP FINANCIAL.RIGEL PHARMACEUTICALS - ENTERED INTO COMMERCIALIZATION LICENSE AGREEMENTS WITH MEDISON PHARMA TO COMMERCIALIZE FOSTAMATINIB IN CANADA & ISRAEL.RIGEL PHARMACEUTICALS - UNDER TERMS, CO WILL RECEIVE UPFRONT PAYMENT OF $5 MILLION, WITH POTENTIAL OF ABOUT $35 MILLION IN REGULATORY & COMMERCIAL MILESTONES.RIGEL PHARMACEUTICALS - ALSO, CO WILL RECEIVE ROYALTY PAYMENTS BEGINNING AT 30% OF NET SALES AFTER CREDIT FOR ADVANCED ROYALTY PAYMENT IS FULFILLED.

Rigel Pharma Posts Q2 Loss Per Share Of $0.12

Aug 6 (Reuters) - Rigel Pharmaceuticals Inc <RIGL.O>::RIGEL ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.12.Q2 EARNINGS PER SHARE ESTIMATE $-0.14 -- REFINITIV IBES DATA.RIGEL PHARMACEUTICALS - AS OF JUNE 30, 2019, HAD CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS OF $112.4 MILLION, VERSUS $128.5 MILLION AS OF DEC 31, 2018.QTRLY TOTAL REVENUES $10.4 MILLION VERSUS $1.8 MILLION.Q2 REVENUE VIEW $9.3 MILLION -- REFINITIV IBES DATA.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up